Rep. Elijah Cummings (D-Maryland) makes remarks after meeting with President Trump over prescription drug pricing, African American communities and voter fraud. With Rep. Peter Welch (D-Vermont).
Plurimi Investment Managers CIO Patrick Armstrong weighs in on his investment strategy, adding that almost everything has been overpriced in the last two months.
Henry “Hank” McKinnell, retired chairman and CEO of Pfizer, weighs in on the future of healthcare and the FDA under the Trump administration.
Chris Raanes, ViewRay CEO, discusses next-generation MRI technology and its role in oncology. With Henry “Hank” McKinnell, retired chairman and CEO of Pfizer.
Pharmaceutical stocks continue to rally despite comments made by President Trump. The "Fast Money" traders discuss weigh in.
John Crowley, Amicus Therapeutics CEO, discusses the slowdown of the company's Galafold launch, FDA regulation and outlook under President Trump.
Juno Therapeutics discontinues cancer drug trial following patient deaths. CNBC's Meg Tirrell reports.
Mylan beat Wall Street expectations with Q4 earnings, but questions still remain about the business. CNBC's Meg Tirrell reports.
The "Fast Money" trader make their case for stocks in the health care sector.
Johnson & Johnson lifts lid on drug pricing data. CNBC's Meg Tirrell reports the details. With the "Fast Money Halftime Report" traders.
Carl Icahn takes a stake in Bristol-Myers Squibb, seeing it as a potential takeover target. CNBC's Meg Tirrell reports. The "Fast Money Halftime Report" traders weigh in.
Arix Bioscience CEO Dr Joe Anderson discusses investment in biotechnology, adding that academic science is the focus of innovation in the industry.
Ari Wald, Oppenheimer, and Max Wolff, Fifty-five Capital, discuss biotech stocks with Brian Sullivan.
Theranos ends the year on thin ice financially, CNBC's Meg Tirrell reports.
Randal Kirk, Intrexon CEO chairman & CEO, discusses the biotech company's advances in genetic engineering.
The “Fast Money” weigh in on the biotech sector, as the iShares Nasdaq Biotechnology ETF IBB continues to surge.
Marathon Pharmaceuticals delays the launch of their $89,000 muscular dystrophy drug amid drug pricing concerns. CNBC's Meg Tirrell reports.
Congress targets Marathon Pharmaceuticals over the company's high drug prices. CNBC's Meg Tirrell reports.
A judge rules Regeneron's cholesterol drug can stay on the market amid the company's ongoing patent case with Amgen. CNBC's Meg Tirrell reports.
Jeremy Levin, Ovid Therapeutics CEO, former Teva Pharmaceuticals CEO, speaks to CNBC's Meg Tirrell about how President Trump's immigration plans may impact the biotech industry.